NWBO stated that 90% of the treatment arm was "crossover" -- that means got a second dose. The 64 in the comparator arm were dosed with DCVax-L in the crossover. As ALL of the patients were blinded, the crossover was the available option to all that progressed -- whether comparator or DCVax-L.
Read the trial protocol: "All patients will have the option to receive DCVax-L in a crossover arm upon documented disease progression." As NWBO stated 90% DCVax-L took the "crossover" DCVax-L dose -- a second dose after progression.
As your mom had a second resection -- did she complete the trial? It confounds the OS data.
Market Data 
Markets 
AI
